



## PartnerRe America Insurance Company Gene & Cell Therapy Formulary (at 10.28.21)

Therapy	FDA Indication	FDA Approval
Allacord®	Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	05.30.2013
Breyanzi®	Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B	02.05.2021
Clevecord®	Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	09.12.2016
Ducord®	Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	10.04.2012
Gintuit®	Mucogingival conditions in adults	03.09.2012
Hemacord®	Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	11.10.2011
HPC, Cord Blood (Clinimune Labs)	Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	05.24.2012



## PartnerRe America Insurance Company Gene & Cell Therapy Formulary (at 10.28.21)

Therapy	FDA Indication	FDA Approval
HPC, Cord Blood (MD Anderson Cord Blood Bank)	For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment	
HPC, Cord Blood (LifeSouth)	For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.	
HPC, Cord Blood (Bloodworks)	•For use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.	2016
Imlygic®	Local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.	10.27.2015
Kymriah®	B-cell precursor Acute Lymphoblastic Leukemia (ALL) that is refractory or in second or later relapse in patients < 25 years old Indicated to treat relapsed or refractory Large B-cell Lymphoma (a type of Non-Hodgkin Lymphoma) after ≥ 2 lines of systemic therapy	08.30.2017 05.01.2018



## PartnerRe America Insurance Company Gene & Cell Therapy Formulary (at 10.28.21)

Therapy	FDA Indication	FDA Approval
Laviv®	Improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.	06.21.2011
Luxturna®	Confirmed biallelic RPE65 mutation-associated Retinal Dystrophy in adults and children ≥ 1 year that have viable retinal cells	12.18.2017
Maci®	Repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.	12.13.2016
Provenge®	Asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.	04.29.2010
Rethymic®	For the treatment of congenital athymia	10.08.2021
Stratagraft®	For the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns).	06.15.2021
Tecartus®	Relapsed or refractory Mantle Cell Lymphoma in adults	07.24.2020

PartnerRe America Insurance Company

6900 Wedgwood Road North, Suite 120 Maple Grove, MN 55311 Phone +1 612 234 4920  
[www.partnerre.com/health](http://www.partnerre.com/health)

3 of 4  
GCTFRM10221



**PartnerRe America Insurance Company Gene & Cell Therapy Formulary (at 10.28.21)**

Therapy	FDA Indication	FDA Approval
Yescarta®	Relapsed or refractory Large B-cell Lymphoma (a type of Non-Hodgkin Lymphoma) in adults after two or more lines of systemic therapy. Includes Diffuse Large B-cell Lymphoma (DLBCL) not otherwise specified, primary Mediastinal Large B-cell Lymphoma, High Grade B-cell Lymphoma, and DLBCL arising from Follicular Lymphoma (types of Non-Hodgkin Lymphoma)	10.18.2017

PartnerRe America Insurance Company  
 6900 Wedgwood Road North, Suite 120 Maple Grove, MN 55311 Phone +1 612 234 4920  
[www.partnerre.com/health](http://www.partnerre.com/health)

4 of 4  
 GCTFRM1021